Large-Scale Study Identifies Shared Genetic Architecture for Polycystic Ovary Syndrome Diagnosis
An international consortium of researchers identify genetic underpinnings associated with PCOS to understand and better diagnose it
In the largest genetic analysis of polycystic ovary syndrome (PCOS) performed to date, an international consortium, including researchers at the Icahn School of Medicine at Mount Sinai, conducted a whole genome association study to identify common genetic architecture for different diagnostic criteria used to define the syndrome. The results are available online in the December 19 issue of the journal PLOS Genetics.
PCOS is among the most common endocrine disorders in reproductive-age women; it is a leading cause of infertility and type 2 diabetes. The origin of PCOS is unknown. It is currently diagnosed based on different sets of clinical criteria, which is controversial and possibly less accurate.
The researchers explored the genetic basis of PCOS by conducting a meta-analysis of seven whole-genome association studies involving more than 10,000 women with PCOS and 100,000 controls of European ancestry. These studies included 2,540 patients diagnosed using the National Institutes of Health criteria (high testosterone and irregular menstrual cycles); 2,669 patients using the Rotterdam criteria (high egg production); and 5,184 self-reported cases from the personal genetics company 23andMe.
With the benefit of this sample size, researchers were able to identify 14 gene variants that were associated with PCOS, including three that were identified for the first time. All the new genetic variants plausibly linked to both metabolic and reproductive features of PCOS.
“One of our most important findings is simply that all the fighting that goes on in the field over which diagnostic criteria to use is unnecessary,” said Andrea Dunaif, MD, Chief of the Hilda and J. Lester Gabrilove Division of Endocrinology, Diabetes, and Bone Disease at the Icahn School of Medicine at Mount Sinai, and one of the senior authors of the study. “We can be pretty broad in our diagnosis with the criteria we have and be assured we are going to find the same genetic forms of PCOS.”
Additional analyses provided further insight into the biology of PCOS. There was evidence that the genetic pathways identified in this study are also linked to other conditions, including obesity, type 2 diabetes, menopause, and depression. In addition, the researchers found for the first time that there are some links to male pattern baldness. The association between PCOS and male-pattern balding is particularly intriguing since it is the first genetic evidence for shared disease biology in men. The genetic link with depression supports epidemiologic studies that have found an increased risk for depression in women with PCOS.
“This study also indicates the enormous power of genome-wide association studies to provide insight into the disease. For the first time, we’re making real progress on understanding the causal pathways leading to PCOS and the diseases that are genetically related to it,” added Dr. Dunaif, an international authority on the disease.
Ultimately, Dr. Dunaif hopes that these biologic insights will enable the development of novel therapies for PCOS.
This work was developed through the international collaboration among 50 institutions. The International PCOS Consortium received funding from a number of organizations, including the National Institutes of Health, European Union’s Horizon 2020 research and innovation program and National Institute of Health Research Biomedical Researcher Centre.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.